Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin alone or with pembrolizumab for HER2-expressing advanced urothelial carcinoma
jRCT2031230309Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (7 cohorts), sponsored by Pfizer. Started Nov 2023; status: active, not recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031230309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230309.